Juvenile arthritis is a group of inflammatory conditions that cause joint swelling, pain, and stiffness in children under 16. The formal term, juvenile idiopathic arthritis (JIA), applies when symptoms last at least six weeks and no other cause can be identified. An estimated 220,000 children and adolescents in the United States have a diagnosed form of arthritis, with prevalence highest among those aged 12 to 17.
Despite the name, juvenile arthritis isn’t simply the adult version of the disease showing up early. It behaves differently, carries unique risks like silent eye inflammation, and in many cases improves significantly by adulthood.
What Causes It
The short answer is that no one knows exactly. JIA is considered autoimmune, meaning the immune system mistakenly attacks the tissue lining the joints. This causes inflammation that, left unchecked, can damage cartilage and bone over time.
The disease likely arises from a combination of genetic and environmental factors. Researchers have identified changes in several genes, particularly those in the HLA (human leukocyte antigen) family, that influence risk. But having those gene variants doesn’t guarantee a child will develop arthritis. Environmental triggers, possibly infections or other immune stressors, appear to play a role in switching the disease on in children who are already genetically susceptible. No single virus, injury, or food has been identified as a definitive trigger.
Types of Juvenile Arthritis
JIA isn’t one disease. It’s an umbrella term covering several subtypes that differ in how many joints are affected and whether symptoms extend beyond the joints.
- Oligoarticular JIA affects four or fewer joints, typically large ones like the knees or ankles. It’s the most common subtype and generally carries the best long-term outlook, though it also has a high risk for eye inflammation.
- Polyarticular JIA involves five or more joints and can affect both large and small joints, including the hands and fingers. It often resembles adult rheumatoid arthritis in pattern, though the underlying biology isn’t identical.
- Systemic JIA affects the whole body, not just the joints. It typically starts with fevers that spike once or twice a day and then return to normal, accompanied by a light pink rash that comes and goes. These whole-body symptoms can persist for at least two weeks before joint swelling becomes obvious. Systemic JIA can also affect internal organs, making it the most serious subtype.
Other less common subtypes include enthesitis-related arthritis, which involves inflammation where tendons attach to bone (often around the heel or knee), and psoriatic arthritis, which occurs alongside the skin condition psoriasis.
How It Feels Day to Day
Joint stiffness is often worst in the morning or after sitting still for a long time. Children may limp, avoid using one hand, or seem unusually clumsy without complaining of pain directly, especially younger kids who may not have the words for what they’re feeling. Swelling can be subtle. A knee that looks slightly puffier than the other may be the only visible sign.
Fatigue is common and often underestimated. The constant low-grade inflammation drains energy, and children with JIA may struggle to keep up with peers during physical activity or at school. Flares, periods when symptoms worsen, can be unpredictable, which makes planning activities frustrating for families.
The Eye Risk Most Parents Don’t Expect
One of the most important things to know about JIA is that it can cause inflammation inside the eye, a condition called uveitis. What makes it particularly dangerous is that it often produces no symptoms at all in the early stages. A child won’t complain of eye pain or blurry vision until significant damage has already occurred.
Because of this, regular eye exams with a slit-lamp (a specialized microscope used by ophthalmologists) are a standard part of JIA care. The frequency of these screenings depends on the subtype of arthritis, the child’s age at diagnosis, and specific lab markers. Children with oligoarticular JIA who are young and test positive for a particular antibody (ANA) face the highest risk. Left untreated, uveitis can lead to vision loss, so keeping up with screening appointments matters enormously even when a child’s joints feel fine.
How It’s Treated
Treatment has changed dramatically over the past two decades. The goal is no longer just managing pain. It’s achieving inactive disease, meaning no swelling, no inflammation on blood tests, and no ongoing joint damage.
For mild cases, anti-inflammatory medications may be enough. When they aren’t, a medication called methotrexate is often the next step. It works by broadly dialing down immune activity and is given once a week, typically as a liquid or tablet for children. It’s been a cornerstone of JIA treatment for decades.
For children who don’t respond adequately to methotrexate, biologic medications have been transformative. These are targeted therapies that block specific proteins driving inflammation. Some block a protein called TNF-alpha, which fuels joint inflammation. Others target different immune signals like interleukin-1 (involved in systemic JIA’s fevers) or interleukin-6. Multiple biologics are now approved specifically for pediatric use, giving doctors several options to match the treatment to the subtype and severity.
Steroid injections directly into a swollen joint can provide rapid relief for individual joints, and oral steroids are sometimes used short-term to bridge the gap while slower-acting medications take effect.
Physical Activity and Physical Therapy
There was a time when children with JIA were told to rest and avoid activity. That advice has been completely reversed. Targeted exercise improves strength, posture, aerobic fitness, and functional mobility while reducing pain. Physical therapy programs also help prevent complications like joint stiffness, muscle contractures, and changes in gait that can develop when a child unconsciously favors a painful joint.
Swimming, cycling, and walking are often well tolerated because they strengthen muscles without putting heavy impact on inflamed joints. The specifics should be tailored to which joints are affected, but the core message is clear: staying active is part of treatment, not something to avoid.
Long-Term Outlook
The prognosis for JIA is better now than at any point in history, largely thanks to biologic therapies. A major Canadian study tracking children to a median age of about 17 found that 47% were in remission and off all medications, while another 25% were in remission but still taking medication to maintain it. About 73% had inactive disease at their last visit.
The flip side of those numbers is worth noting. Roughly one in four young adults with JIA still had active disease as they transitioned out of pediatric care, and about half were still on some form of treatment. JIA is not something every child simply “grows out of.” For a significant minority, it becomes a chronic condition that carries into adulthood and requires ongoing management.
Compared to earlier generations, though, permanent joint damage has become less common. Early, aggressive treatment with modern medications is the main reason. Children diagnosed today and treated promptly have a meaningfully better chance of reaching adulthood with joints that function normally.